JP2023106366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023106366A5 JP2023106366A5 JP2023062212A JP2023062212A JP2023106366A5 JP 2023106366 A5 JP2023106366 A5 JP 2023106366A5 JP 2023062212 A JP2023062212 A JP 2023062212A JP 2023062212 A JP2023062212 A JP 2023062212A JP 2023106366 A5 JP2023106366 A5 JP 2023106366A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- formula
- pharma
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical group 0.000 claims 56
- 150000003839 salts Chemical class 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000002947 alkylene group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000005549 heteroarylene group Chemical group 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000732 arylene group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 229910005965 SO 2 Inorganic materials 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004474 heteroalkylene group Chemical group 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000005001 aminoaryl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 150000001717 carbocyclic compounds Chemical class 0.000 claims 1
- 125000004452 carbocyclyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- -1 nitro, cyano, amino Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 102000013498 tau Proteins Human genes 0.000 claims 1
- 108010026424 tau Proteins Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024209477A JP2025060612A (ja) | 2017-07-12 | 2024-12-02 | タウタンパク質分解の化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531773P | 2017-07-12 | 2017-07-12 | |
| US62/531,773 | 2017-07-12 | ||
| JP2020501505A JP7260521B2 (ja) | 2017-07-12 | 2018-07-12 | タウタンパク質分解の化合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501505A Division JP7260521B2 (ja) | 2017-07-12 | 2018-07-12 | タウタンパク質分解の化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024209477A Division JP2025060612A (ja) | 2017-07-12 | 2024-12-02 | タウタンパク質分解の化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023106366A JP2023106366A (ja) | 2023-08-01 |
| JP2023106366A5 true JP2023106366A5 (enExample) | 2024-04-16 |
Family
ID=65001509
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501505A Active JP7260521B2 (ja) | 2017-07-12 | 2018-07-12 | タウタンパク質分解の化合物 |
| JP2023062212A Withdrawn JP2023106366A (ja) | 2017-07-12 | 2023-04-06 | タウタンパク質分解の化合物 |
| JP2024209477A Pending JP2025060612A (ja) | 2017-07-12 | 2024-12-02 | タウタンパク質分解の化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501505A Active JP7260521B2 (ja) | 2017-07-12 | 2018-07-12 | タウタンパク質分解の化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024209477A Pending JP2025060612A (ja) | 2017-07-12 | 2024-12-02 | タウタンパク質分解の化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210154184A1 (enExample) |
| EP (2) | EP4310496A3 (enExample) |
| JP (3) | JP7260521B2 (enExample) |
| AU (1) | AU2018300982B2 (enExample) |
| CA (1) | CA3069181A1 (enExample) |
| ES (1) | ES2965049T3 (enExample) |
| WO (1) | WO2019014429A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2894994C (en) | 2012-12-21 | 2019-11-12 | National Institute Of Radiological Sciences | Compounds for imaging tau proteins that accumulate in brain |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| KR20230127371A (ko) * | 2016-11-01 | 2023-08-31 | 아비나스 오퍼레이션스, 인코포레이티드 | 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법 |
| KR20190134997A (ko) | 2017-02-17 | 2019-12-05 | 데날리 테라퓨틱스 인크. | 항-tau 항체 및 이의 사용 방법 |
| CA3069181A1 (en) * | 2017-07-12 | 2019-01-17 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
| HRP20230183T1 (hr) | 2017-12-21 | 2023-05-12 | Ribon Therapeutics Inc. | Kinazolinoni kao inhibitori parp14 |
| EP3774804A1 (en) | 2018-03-26 | 2021-02-17 | Novartis AG | N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives |
| EP3774772A1 (en) * | 2018-04-13 | 2021-02-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| EP4272737A3 (en) | 2018-04-23 | 2024-01-17 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
| JP7293343B2 (ja) | 2018-05-09 | 2023-06-19 | アプリノイア セラピューティクス リミテッド | ヘテロアリール化合物及びその使用 |
| EP3831811A4 (en) | 2018-07-31 | 2022-04-20 | Fimecs, Inc. | HETEROCYCLIC COMPOUND |
| CN112912376A (zh) | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物 |
| US11389438B2 (en) * | 2019-02-25 | 2022-07-19 | Chdi Foundation, Inc. | Compounds for targeting mutant huntingtin protein and uses thereof |
| KR20210152515A (ko) | 2019-04-12 | 2021-12-15 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| MA56513A (fr) * | 2019-06-19 | 2022-04-27 | Ribon Therapeutics Inc | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie |
| US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
| EP4031247A1 (en) * | 2019-09-16 | 2022-07-27 | Novartis AG | Bifunctional degraders and their methods of use |
| KR20220100921A (ko) * | 2019-11-13 | 2022-07-18 | 아프리노이아 테라퓨틱스 리미티드 | 타우 단백질 응집체를 분해하기 위한 화합물 및 이의 용도 |
| CN110878095B (zh) * | 2019-12-02 | 2023-01-24 | 中山大学 | 一种姜黄素双功能分子及其制备方法和应用 |
| CA3171337A1 (en) * | 2020-03-18 | 2021-09-23 | Dana-Farber Cancer Institute, Inc. | Targeted degraders of aberrant tau based on the pet tracer pbb3 |
| US20230312639A1 (en) * | 2020-04-23 | 2023-10-05 | University Of Iowa Research Foundation | Gper proteolytic targeting chimeras |
| EP4149505A1 (en) * | 2020-05-15 | 2023-03-22 | Vib Vzw | Means and methods for the treatment of pathological aggregation |
| WO2021242982A1 (en) * | 2020-05-28 | 2021-12-02 | Bristol-Myers Squibb Company | Galectin-3 inhibitors |
| CA3181979A1 (en) * | 2020-06-17 | 2021-12-23 | Fleur M. FERGUSON | Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an e3-ligase system |
| WO2022201063A1 (en) * | 2021-03-23 | 2022-09-29 | Covabind Joint Research Private Limited | Nanoparticle composition for targeted protein degradation |
| EP4337259A1 (en) | 2021-05-14 | 2024-03-20 | Aprinoia Therapeutics Limited | Compounds for degrading alpha-synuclein aggregates and uses thereof |
| AU2022288713A1 (en) | 2021-06-07 | 2023-12-21 | Dana-Farber Cancer Institute, Inc. | Inhibitors of ttbk1 |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| WO2023036936A1 (en) * | 2021-09-09 | 2023-03-16 | Booster Therapeutics Gmbh | Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods) |
| EP4147723A1 (en) | 2021-09-09 | 2023-03-15 | Booster Therapeutics GmbH | Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods) |
| WO2024081690A2 (en) * | 2022-10-11 | 2024-04-18 | The General Hospital Corporation | Engineered bifunctional receptors and uses thereof |
| WO2024182633A2 (en) * | 2023-03-01 | 2024-09-06 | The Regents Of The University Of California | Targeted dephosphorylation of tau |
| CN116344058B (zh) * | 2023-05-29 | 2023-08-18 | 之江实验室 | 一种基于图信号的阿尔兹海默风险标注方法及装置 |
| WO2025117551A1 (en) * | 2023-11-27 | 2025-06-05 | Amydis, Inc. | Amino acid derivatives for detecting neurological disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8932557B2 (en) * | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
| US9378662B2 (en) | 2011-08-04 | 2016-06-28 | Ats Holdings Llc | Simplified spine testing device |
| EP3049411B1 (en) * | 2013-09-26 | 2017-04-26 | F. Hoffmann-La Roche AG | Imidazo[1,2-a]pyridin-7-amines as imaging tools |
| TW201605852A (zh) * | 2013-09-26 | 2016-02-16 | 美國禮來大藥廠 | 新穎化合物及其製備ｔａｕ造影劑及ｔａｕ造影調配物之用途 |
| EP3061748A4 (en) * | 2013-10-22 | 2017-04-05 | Clino Ltd. | Tau imaging probe |
| KR20250127179A (ko) * | 2014-04-14 | 2025-08-26 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| WO2016197032A1 (en) * | 2015-06-04 | 2016-12-08 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| RU2018105094A (ru) * | 2015-07-13 | 2019-08-14 | Арвинас, Инк. | Модуляторы протеолиза на основе аланина и связанные с ними способы применения |
| EP3331905B1 (en) * | 2015-08-06 | 2022-10-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| US10772962B2 (en) * | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| KR20230127371A (ko) * | 2016-11-01 | 2023-08-31 | 아비나스 오퍼레이션스, 인코포레이티드 | 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법 |
| CN106543185B (zh) * | 2016-11-10 | 2017-12-15 | 吉林大学 | 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| CA3069181A1 (en) * | 2017-07-12 | 2019-01-17 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
-
2018
- 2018-07-12 CA CA3069181A patent/CA3069181A1/en active Pending
- 2018-07-12 EP EP23195169.0A patent/EP4310496A3/en active Pending
- 2018-07-12 JP JP2020501505A patent/JP7260521B2/ja active Active
- 2018-07-12 AU AU2018300982A patent/AU2018300982B2/en active Active
- 2018-07-12 EP EP18831849.7A patent/EP3652329B1/en active Active
- 2018-07-12 WO PCT/US2018/041787 patent/WO2019014429A1/en not_active Ceased
- 2018-07-12 ES ES18831849T patent/ES2965049T3/es active Active
- 2018-07-12 US US16/630,294 patent/US20210154184A1/en not_active Abandoned
-
2023
- 2023-04-06 JP JP2023062212A patent/JP2023106366A/ja not_active Withdrawn
- 2023-05-23 US US18/200,950 patent/US20240091213A1/en active Pending
-
2024
- 2024-12-02 JP JP2024209477A patent/JP2025060612A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023106366A5 (enExample) | ||
| JP2020527559A5 (enExample) | ||
| JP2012507522A5 (enExample) | ||
| JP7715911B2 (ja) | 神経筋疾患の処置のためのピリダジノン化合物 | |
| RU2009104764A (ru) | Производные пурина, как антангонисты a2a | |
| JP2008517983A5 (enExample) | ||
| CA2511479A1 (en) | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity | |
| EP2963033A1 (en) | Benzimidazole-4-carboxamide derivates, their preparation methods, pharmaceutical compositions and their uses | |
| WO2020097258A1 (en) | Pyridazinone compounds and uses thereof | |
| WO2014164667A1 (en) | Dengue and west nile virus protease inhibitors | |
| WO1996018607A1 (en) | Aniline derivative having the effect of inhibiting nitrogen monoxide synthase | |
| IL280075B1 (en) | A conjugated tricyclic compound as a dual PDE3/PDE4 inhibitor | |
| JP2005533013A5 (enExample) | ||
| WO2010135427A2 (en) | Trioxane monomers and dimers | |
| US20240308984A1 (en) | Jak Inhibitor With High Oral Bioavailability | |
| CN102526087B (zh) | 核苷类化合物在制备治疗肠病毒71(ev71)感染疾病药物的应用 | |
| JP2007505044A5 (enExample) | ||
| JP2008524218A5 (enExample) | ||
| JP4393376B2 (ja) | フェニルシクロヘキシルプロパノールアミン誘導体、その製造法、およびその治療的適用 | |
| RU2012109220A (ru) | Новые соединения и их терапевтическое использование для ингибирования протеинкиназы | |
| JPH01168677A (ja) | 向精神性非環式アミド誘導体 | |
| CN115724780B (zh) | 一种基于疏水标签的酰基硫脲类化合物及其制备方法与抗甲型流感病毒的应用 | |
| RU2011101661A (ru) | Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний | |
| JP2025500176A (ja) | カルボン酸バイオアイソスタを含むｄｈｏｄｈ阻害剤 | |
| CN113354708A (zh) | 作为Caspase抑制剂的联环化合物 |